-
1Academic Journal
Authors: K. M. Nyushko, B. Ya. Alekseev, A. S. Kalpinsky, A. D. Kaprin, К. М. Нюшко, Б. Я. Алексеев, А. С. Калпинский, А. Д. Каприн
Source: Cancer Urology; Том 10, № 4 (2014); 70-74 ; Онкоурология; Том 10, № 4 (2014); 70-74 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2014-10-4
Subject Terms: кардиоваскулярный риск, luteinizing hormone-releasing hormone analogues and antagonists, degarelix, castration-refractoriness, cardiovascular disease, cardiovascular risk, аналоги и антагонисты лютеинизирующего гормона рилизинг-гормона, дегареликс, кастрационная рефрактерность, сердечно-сосудистая патология
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/399/416; Состояние онкологической помощи населению России в 2012 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2013.; Huggins C., Hoges C.V. Studies on prostate cancer. The effect of castration. Cancer Res 1941:385–402.; Malkowicz S.B. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58(2 Suppl 1):108–13.; Kaisary A.V., Tyrrell C.J., Peeling W.B. et al. Comparison of LHRH analogue with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67(5):502–8.; Keating N.L., O'Malley A.J., Freedland S.J. et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. JNCI J Natl Cancer Inst 2010;102:39–46.; Bubley G.J. Is the flare phenomenon clinically significant? Urology 2001;58 (2 Suppl 1):5–9.; Bertaglia V., Tucci M., Fiori C. et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer 2013;11(3):325–30.; Rick F.G., Block N.L., Schally A.V. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther 2013;6:391–402.; Anderson J. Degarelix: a novel gonadotropin-releasing hormone blocker for the treatment of prostate cancer. Future Oncol 2009;5(4):433–43.; Persson B.E., Kold Olesen T., Jensen J.K. Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 2009;90(3):235–44.; Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11):1531–8.; Crawford E.D., Shore N.D., Moul J.W. et al. Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. Urology 2014;83(5):1122–8.; Klotz L., Miller K., Crawford E.D. et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormonereleasing hormone agonists. Eur Urol 2014 Jan 9. pii: S0302–2838(13)01491–7.; Miller K., Rüssel C., Goble S. et al. Open-label, exploratory study of degarelix as second-line hormonal therapy in patients with prostate cancer (CS27). EAU 2013; Poster 678.; Van Poppel H., Klotz L. Gonadotropinreleasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19(7):594–601.; Smith M.R., Klotz L., van der Meulen E. et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol 2011;186(5): 1835–42.; Tanriverdi F., Gonzalez-Martinez D., Hu Y. et al. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol 2005;142(1):103–10.; Chen H.F., Jeung E.B., Stephenson M., Leung P.C. Human peripheral blood mononuclear cells express gonadotropinreleasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84(2):743–50.; https://oncourology.abvpress.ru/oncur/article/view/399
-
2Academic Journal
Authors: A. S. Markova, V. B. Matveev, А. С. Маркова, В. Б. Матвеев
Source: Cancer Urology; Том 10, № 1 (2014); 76-81 ; Онкоурология; Том 10, № 1 (2014); 76-81 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2014-10-1
Subject Terms: дегареликс, androgen deprivation therapy, luteinizing hormone releasing hormone antagonists, degarelix, андрогендепривационная терапия, антагонисты лютеинизирующего гормона рилизинг-гормона
File Description: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/25/40; Heidenreich A., Bastian P. J., Bellmunt J. et al. EAU Guidelines 2013; p. 1–154.; Payne H., Mason M. Androgen deprivation therapy as adjuvant / neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer 2011;105:1628–34.; Sharifi N., Gulley J. L., Dahut W. L. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 2010;17: 305–15.; Gittelman M., Pommerville P. J., Persson B. E. et al. A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 2008;180:1986–92.; Klotz L., Boccon-Gibod L., Shore N. D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531–8.; Van Poppel H., Tombal B., de la Rosette J. L. еt al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805–13.; Koechling W., Hjortkjaer R., Tankу L. B. Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples. Br J Clin Pharmacol 2010;70:580–7.; Bhasin S., Berman N., Swerdloff R. S. Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment. J Androl 1994;15:386–91.; Varenhorst E., Wallentin L., Carlstrцm K. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate. Scand J Urol Nephrol 1982;16:31–6.; Ben-Josef E., Yang S. Y., Ji T. H. et al. Hormone-refractory prostate cancer cells express functional follicle-stimulating hormone receptor (FSHR). J Urol 1999;161:970–6.; Mariani S., Salvatori L., Basciani S. et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol 2006;175:2072–7.; Radu A., Pichon C., Camparo P. et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med 2010;363:1621–30.; Canon J. G., Kraj B., Sloan G. Follicle-stimulating hormone promotes RANK expression on human monocytes. Cytokin 2011;53:141–4.; Tombal B., Berges R. Optimal control of testosterone: a clinical case-based approach of modern androgen-deprivation therapy. Eur Urol Suppl 2008;7:15–21.; Tombal B. Appropriate castration with luteinising hormone releasing hormone (LHRH) agonists: what is the optimal level of testosterone? Eur Urol Suppl 2005;4:14–9.; Perachino M., Cavalli V., Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int 2010; 105:648–51.; Miller K., Crawford D., Shore N. et al. Disease control-related outcomes from an analysis of six comparative randomized сlinical trials of degarelix versus luteinising hormone-releasing hormone (LHRH) agonists. 28 th EAU Congress. Milan, Italy. Poster 678.; Tombal B., Miller K., Boccon-Gibod L. et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol 2010;57:836–2.; Tombal B., Albertsen P., de la Taille A. et al. Lower risk of cardiovascular (CV) events and death in men receiving ADTby gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists. 28 th EAU Congress. Milan, Italy. Poster 677.; Albertsen P. C., Klotz L., Tombal B. et al. Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist. Eur Urol 2014;65:565–73.; Axcrona K., Aaltomaa S., da Silva C. M. et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int 2012;110 (11):1721–8.; Mason M., Maldonado Pijoan X., Steidle C. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus gosere-lin plus bicalutamide. Clin Oncol (R Coll Ra-diol) 2013;25 (3):190–6.; Albertsen P. C., Moore D. F., Shih W. et al. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011;29 (10):1335–41.; Conteduca V., DiLorenzo G., Tartaron A., Aita M. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer. An unresolved controversy. Crit Rev Oncol Hematol 2013;86:42–51.; Shahani S., Braga-Basaria M., Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 2008;93:2042–9.; Smith M. R., Finkelstein J. S., McGovern F. J. et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87 (2):599–603.; Smith M. R., Lee H., Nathan D. M. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305–8.; Stanworth R. D., Jones T. H. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009;37:74–90.; D’Amico A. V., Denham J. W., Crook J. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420–5.; Keating N. L., O’Malley A. J., Freedland S. J., Smith M. R. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010;102:39–43.; Keating N. L., O’Malley A. J., Smith M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24: 4448–56.; Levine G. N., D’Amico A. V., Berger P. et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010;121:833–40.; Saigal C. S., Gore J. L., Krupski T. L. et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493–500.; Tsai H. K., D’Amico A. V., Sadetsky N. et al. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Institute 2007;99:1516–24.; Alibhai S. M., Duong-Hua M., Sutradhar R. et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009; 7:3452–58.; Roach M., Bae K., Speight J. et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 2008;26:585–91.; Studer U. E., Whelan P., Albrecht W. et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006;24:1868–76.; Chen H. F., Jeung E. B., Stephenson M., Leung P. C. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab 1999;84 (2):743–50.; Andersson J., Libby P., Hansson G. K. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134 (1):33–46.; https://oncourology.abvpress.ru/oncur/article/view/25
-
3Academic Journal
Authors: Nyushko K.M., Alekseev B.Ya., Kalpinsky A.S., Kaprin A.D.
Source: Onkourologiya
Subject Terms: рак предстательной железы, аналоги и антагонисты лютеинизирующего гормона рилизинг-гормона, дегареликс, кастрационная рефрактерность, сердечно-сосудистая патология, кардиоваскулярный риск
Availability: https://repository.rudn.ru/records/article/record/132572/